Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · IEX Real-Time Price · USD
75.21
+0.43 (0.58%)
May 3, 2024, 4:00 PM EDT - Market closed
Dr. Reddy's Laboratories Employees
Dr. Reddy's Laboratories had 25,863 employees on March 31, 2023. The number of employees increased by 1,068 or 4.31% compared to the previous year.
Employees
25,863
Change (1Y)
1,068
Growth (1Y)
4.31%
Revenue / Employee
$115,657
Profits / Employee
$21,199
Market Cap
12.52B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2023 | 25,863 | 1,068 | 4.31% |
Mar 31, 2022 | 24,795 | 2,056 | 9.04% |
Mar 31, 2021 | 22,739 | 1,089 | 5.03% |
Mar 31, 2020 | 21,650 | -316 | -1.44% |
Mar 31, 2019 | 21,966 | -1,558 | -6.62% |
Mar 31, 2018 | 23,524 | 853 | 3.76% |
Mar 31, 2017 | 22,671 | 496 | 2.24% |
Mar 31, 2016 | 22,175 | 1,802 | 8.85% |
Mar 31, 2015 | 20,373 | 1,952 | 10.60% |
Mar 31, 2014 | 18,421 | 1,804 | 10.86% |
Mar 31, 2013 | 16,617 | 1,417 | 9.32% |
Mar 31, 2012 | 15,200 | 277 | 1.86% |
Mar 31, 2011 | 14,923 | 1,468 | 10.91% |
Mar 31, 2010 | 13,455 | 2,227 | 19.83% |
Mar 31, 2009 | 11,228 | 1,653 | 17.26% |
Mar 31, 2008 | 9,575 | 555 | 6.15% |
Mar 31, 2007 | 9,020 | 1,495 | 19.87% |
Mar 31, 2006 | 7,525 | 1,390 | 22.66% |
Mar 31, 2005 | 6,135 | -20 | -0.32% |
Mar 31, 2004 | 6,155 | 303 | 5.18% |
Mar 31, 2003 | 5,852 | 409 | 7.51% |
Mar 31, 2002 | 5,443 | 314 | 6.12% |
Mar 31, 2001 | 5,129 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG & Co. KGaA | 119,845 |
Viatris | 38,000 |
Revvity | 11,500 |
Medpace Holdings | 5,900 |
Insulet | 3,000 |
ShockWave Medical | 1,468 |
Neurocrine Biosciences | 1,400 |
Sarepta Therapeutics | 1,314 |
RDY News
- 3 days ago - Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S. - Business Wire
- 6 weeks ago - Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK - Business Wire
- 3 months ago - Dr. Reddy's Q3 & 9M FY24 Financial Results - Business Wire
- 4 months ago - Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women's Health and Dietary Supplements Portfolio of Brands - Business Wire
- 5 months ago - Dr. Reddy's becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index - Business Wire
- 5 months ago - Coya Therapeutics, Inc. and Dr. Reddy's Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS) - Business Wire
- 5 months ago - India's Dr. Reddy's R&D centre being inspected by US FDA - Reuters
- 6 months ago - Dr. Reddy's Q2 FY24 Financial Results - Business Wire